MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

ESPERION THERAPEUTICS INC

Cerrado

SectorSalud

1.17 -4.88

Resumen

Variación precio

24h

Actual

Mínimo

1.14

Máximo

1.26

Métricas clave

By Trading Economics

Ingresos

-19M

-40M

Ventas

-4.1M

65M

BPA

-0.206

Margen de beneficio

-62.243

Empleados

304

EBITDA

-16M

-21M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+481.45% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

76M

234M

Apertura anterior

6.05

Cierre anterior

1.17

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

131 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

ESPERION THERAPEUTICS INC Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 jul 2025, 21:01 UTC

Ganancias

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

18 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Basic Materials Roundup: Market Talk

18 jul 2025, 20:46 UTC

Ganancias

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 jul 2025, 20:39 UTC

Adquisiciones, fusiones, absorciones

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 20:36 UTC

Ganancias

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 jul 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 jul 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 jul 2025, 20:02 UTC

Charlas de Mercado

Gold Higher to Close Out Week -- Market Talk

18 jul 2025, 19:14 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 jul 2025, 19:06 UTC

Charlas de Mercado

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 jul 2025, 18:24 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 jul 2025, 18:19 UTC

Ganancias

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 jul 2025, 18:11 UTC

Adquisiciones, fusiones, absorciones

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 jul 2025, 18:11 UTC

Ganancias

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 jul 2025, 17:35 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 jul 2025, 16:29 UTC

Charlas de Mercado

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 jul 2025, 16:28 UTC

Adquisiciones, fusiones, absorciones

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 jul 2025, 16:22 UTC

Ganancias

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

18 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Basic Materials Roundup: Market Talk

18 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

18 jul 2025, 16:04 UTC

Ganancias

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 jul 2025, 15:58 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

18 jul 2025, 15:58 UTC

Charlas de Mercado

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 jul 2025, 15:47 UTC

Charlas de Mercado
Ganancias

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparación entre iguales

Cambio de precio

ESPERION THERAPEUTICS INC Esperado

Precio Objetivo

By TipRanks

481.45% repunte

Estimación a 12 meses

Media 7.21 USD  481.45%

Máximo 16 USD

Mínimo 1.85 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ESPERION THERAPEUTICS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

3

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

0.85 / 1.05Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

131 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.